Methods for prognosing and preventing metastatic liver disease
AssigneeCornell University
InventorsDavid C. Lyden, Bruno Costa Da Silva
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method for identifying an individual who is at risk for developing metastatic liver disease that involves measuring, in a sample isolated from the individual, exosomal levels of one or more markers of metastatic liver disease. Kits for carrying out this method are also disclosed. The present invention also relates to a method of preventing metastatic liver disease in an individual who are at risk for developing the disease that involves administering one or more inhibitors of liver pre-metastatic niche formation.
Claims7
A method comprising:
- selecting a subject having a pancreatic lesion;
- obtaining, from the selected subject, a sample containing exosomes;
- isolating exosomes from said sample;
- and
- detecting, in said isolated exosomes, protein levels of Annexin A1 (ANXA1), filamin A (FLNA), lectin galactoside-binding soluble 3 (LGALS3), and macrophage migration inhibitory factor (MIF).
A method of inhibiting metastatic liver disease in a subject, said method comprising:
- selecting a subject having a pancreatic lesion and increased exosomal levels of proteins Annexin A1 (ANXA1), filamin A (FLNA), lectin galactoside-binding soluble 3 (LGALS3), and macrophage migration inhibitory factor (MIF) relative to exosomal levels of said proteins in a subject not having a pancreatic lesion, and
- administering to the selected subject, an inhibitor of liver pre-metastatic niche (LPMN) formation in an amount effective to inhibit metastatic liver disease in the subject.
Dependencies are inferred from the claim text.